# Off-the-shelf natural killer cells to sweep up residual disease

Source: https://onco.cc/ideas/idea-bio2-nk-cells-for-mrd/  
OnCo record `idea-bio2-nk-cells-for-mrd` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Donor immune cells that need no matching could be given as short courses to clear the few cancer cells left after surgery, when the target is smallest.

## Summary

Allogeneic natural killer and CAR-NK products have been limited by short persistence and modest activity against bulky solid tumours, but persistence matters far less when the target is a handful of disseminated cells. Combined with a cytokine support agent, repeat dosing in the molecular residual disease window is a rational use of a product class that has struggled in advanced disease.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Repeat-dosed allogeneic NK cell therapy converts ctDNA-positive post-surgical patients to ctDNA-negative more often than standard care, with no cytokine release syndrome above grade 2.
- Rationale: NK cells kill single cells in circulation and marrow efficiently and do not require antigen presentation or HLA matching, so they suit a low-burden, wide-antigen setting. Off-the-shelf supply makes rapid treatment after a positive test feasible.
- Proposed test: A phase 2 single-arm study in ctDNA-positive colorectal or breast cancer with molecular clearance at six months as primary endpoint, and paired marrow sampling to confirm disseminated cell clearance.
- Maturity: preclinical-evidence
- Actor: industry

## Sources

- Bottleneck evidence (Dormant cells and minimal residual disease): Tie et al., ctDNA analysis guiding adjuvant therapy in stage II colon cancer (NEJM 2022): https://doi.org/10.1056/NEJMoa2200075

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-NK & CAR-macrophage](https://onco.cc/technologies/car-nk-macrophage/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- companies: [Fate Therapeutics](https://onco.cc/companies/fate-therapeutics/), [ImmunityBio](https://onco.cc/companies/immunitybio/), [Nkarta](https://onco.cc/companies/nkarta/)
- terms: [Cytokine release syndrome (CRS)](https://onco.cc/terms/crs/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- bottlenecks: [Dormant cells and minimal residual disease](https://onco.cc/bottlenecks/b-dormancy-mrd/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-nk-cells-for-mrd.json